Literature DB >> 6857148

Antibody response to pneumococcal vaccination in patients with myelomatosis.

H S Birgens, F Espersen, J B Hertz, F K Pedersen, A Drivsholm.   

Abstract

17 patients with myelomatosis were vaccinated with a 14-valent pneumococcal capsular polysaccharide vaccine. In comparison to 12 healthy controls, they had statistically significant lower combined geometric mean antibody concentrations (the geometric means of all 14 antigens), both before and 4 weeks after the immunization. Mean antibody increases, however, were remarkably similar in the 2 groups. After 18 months the geometric mean antibody concentrations of the patient group had returned to preimmunization levels or lower for 7 out of 14 antigens. 1 case of pneumococcal bacteraemia occurred in the patient group 8 1/2 months after vaccination in spite of a significant initial antibody response against the infecting serotype 23 F. Pneumococcal vaccination in patients with myelomatosis appears to yield subnormal antibody responses and therefore probably insufficient protection against pneumococcal infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6857148     DOI: 10.1111/j.1600-0609.1983.tb01500.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  7 in total

Review 1.  Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma.

Authors:  A Winkelstein; P S Jordan
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

Review 2.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

3.  Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function.

Authors:  L M Pilarski; E J Andrews; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

4.  Immunological factors and risk of infection in plateau phase myeloma.

Authors:  R M Hargreaves; J R Lea; H Griffiths; J A Faux; J M Holt; C Reid; C Bunch; M Lee; H M Chapel
Journal:  J Clin Pathol       Date:  1995-03       Impact factor: 3.411

5.  Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.

Authors:  Sebastian Kobold; Tim Luetkens; Britta Marlen Bartels; Yanran Cao; York Hildebrandt; Orhan Sezer; Henrike Reinhard; Julia Templin; Katrin Bartels; Nesrine Lajmi; Friedrich Haag; Carsten Bokemeyer; Nicolaus Kröger; Djordje Atanackovic
Journal:  Clin Dev Immunol       Date:  2012-03-12

6.  Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan.

Authors:  Mohammad Faizan Zahid; Natasha Ali; Myra Nasir; Maria Haider Baig; Mustafa Iftikhar; Syed Usman Bin Mahmood; Arhama Malik; Sara Atif; Mohammad Asim Beg
Journal:  Hematol Transfus Cell Ther       Date:  2019-06-14

Review 7.  Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Sarah M Tete; Marc Bijl; Surinder S Sahota; Nicolaas A Bos
Journal:  Front Immunol       Date:  2014-06-03       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.